Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

The goal of this clinical trial is to learn if a combination of atezolizumab and standard chemotherapy works to treat sensitive Extensive-stage Small Cell Lung Cancer, progressing after first-line of treatment. The main questions it aims to answer are: * Does combination of atezolizumab and standard chemotherapy increase overall survival? * What medical problems do participants have when taking combination of atezolizumab and standard chemotherapy? Participants will: * take atezolizumab and standard chemotherapy every 3 weeks for 4 cycles and than atezolizumab every 3 weeks up to 18 cycles

Trial Details

NCT ID
NCT06663098
Phase
PHASE2
Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Atezolizumab
  • Carboplatin
  • Etoposide
Locations (sample)
  • Aviano (PN), Italy|46.07056,12.59472
  • Bari, Italy|41.12066,16.86982
  • Bologna, Italy|44.49381,11.33875
  • Carpi, Italy|44.78237,10.8777
  • Cremona, Italy|45.13325,10.02129

Key Eligibility Criteria

  • Diagnosis of small-cell lung cancer (SCLC) (according to WHO classification 2015) confirmed at pathology (histology or cytology).
  • Male or female and ≥ 18 years of age.
  • Life expectancy ≥ 12 weeks.
  • Disease progression at least 60 days after the completion of first-line chemotherapy consisting of at least 4 cycles of platinum-etoposide plus eit…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →